Literature DB >> 18490076

Effects of N-acetylcysteine administration in hepatic microcirculation of rats with biliary cirrhosis.

Ying-Ying Yang1, Kuei-Chuan Lee, Yi-Tsau Huang, Ying-Wen Wang, Ming-Chih Hou, Fa-Yauh Lee, Han-Chieh Lin, Shou-Dong Lee.   

Abstract

BACKGROUND/AIMS: Increased intrahepatic resistance (IHR) in cirrhosis is due to fibrosis and hepatic endothelial dysfunction (HED). Besides producing fibrosis, increased reactive oxygen species (ROS) promotes ROS-related nitration of anti-oxidative enzymes in cirrhotic livers. Tyrosine nitration (nitrotyrosilation)-related inactivation of anti-oxidative enzymes is increased in cirrhotic livers. This study investigates effects of N-acetylcysteine (NAC) administrations in bile-duct-ligation (BDL) rats.
METHODS: This study measured portal venous pressure (PVP), IHR, hepatic endothelial function, hepatic levels of anti-oxidants and oxidants, type III procollagen (PIIIP), proteins expression of thromboxane synthase (TXS), nitrotyrosine, manganese superoxide dismutase (MnSOD), and hepatic NOx and thromboxane A(2) (TXA(2)) production in perfusates.
RESULTS: The improvement of HED was associated with decreased PVP and IHR, hepatic protein and mRNA levels of PIIIP, protein expression of TXS and nitrotyrosine, oxidants and production of TXA(2) in NAC-treated BDL rat livers. Conversely, hepatic NOx production, anti-oxidants, and protein expression of MnSOD were increased in NAC-treated BDL rat livers.
CONCLUSIONS: In NAC-treated cirrhotic rats, the decrease in IHR was mainly caused by its anti-oxidative effect-related prevention of hepatic fibrogenesis associated with the decrease of oxidants-related nitrotyrosilation and improvement of HED.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18490076     DOI: 10.1016/j.jhep.2008.02.012

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  12 in total

1.  Immunohistopathological changes in murine Schistosomiasis mansoni under the influence of N-acetyl-L-cysteine.

Authors:  André de Lima Aires; Mônica Camelo Pessôa de Azevedo Albuquerque; Renata Alexandre Ramos Silva; Giuliana Viegas Schirato; Nicodemos Teles de Pontes Filho; Sidcley Bernardino de Araújo; Valdênia Maria Oliveira Souza; Vlaudia Maria Assis Costa; Elizabeth Malagueño
Journal:  Parasitol Res       Date:  2012-07-07       Impact factor: 2.289

Review 2.  Endothelial dysfunction in cirrhosis: Role of inflammation and oxidative stress.

Authors:  Balasubramaniyan Vairappan
Journal:  World J Hepatol       Date:  2015-03-27

Review 3.  New cellular and molecular targets for the treatment of portal hypertension.

Authors:  Jordi Gracia-Sancho; Raquel Maeso-Díaz; Anabel Fernández-Iglesias; María Navarro-Zornoza; Jaime Bosch
Journal:  Hepatol Int       Date:  2015-03-05       Impact factor: 6.047

4.  Relevance of plasma malondialdehyde level and severity of portal hypertension in cirrhotic patients.

Authors:  Sheng-Lan Wang; Xin-Yan Zhu; Dong-Wei Zhang; Zhao-Jie Zhang; Heng-Jun Gao; Chang-Qing Yang
Journal:  Int J Clin Exp Med       Date:  2015-07-15

Review 5.  Pathophysiology of portal hypertension.

Authors:  Yasuko Iwakiri
Journal:  Clin Liver Dis       Date:  2014-02-25       Impact factor: 6.126

6.  Cholestatic liver disease results increased production of reactive aldehydes and an atypical periportal hepatic antioxidant response.

Authors:  Colin T Shearn; Blair Fennimore; David J Orlicky; Yue R Gao; Laura M Saba; Kayla D Battista; Stefanos Aivazidis; Mohammed Assiri; Peter S Harris; Cole Michel; Gary F Merrill; Edward E Schmidt; Sean P Colgan; Dennis R Petersen
Journal:  Free Radic Biol Med       Date:  2019-08-01       Impact factor: 7.376

7.  Increased plasma malondialdehyde in patients with viral cirrhosis and its relationships to plasma nitric oxide, endotoxin, and portal pressure.

Authors:  Kuei-Chuan Lee; Ying-Ying Yang; Ying-Wen Wang; Fa-Yauh Lee; Che-Chuan Loong; Ming-Chih Hou; Han-Chieh Lin; Shou-Dong Lee
Journal:  Dig Dis Sci       Date:  2009-10-14       Impact factor: 3.199

8.  S-nitroso-N-acetylcysteine attenuates liver fibrosis in cirrhotic rats.

Authors:  Rafael Vercelino; Irene Crespo; Gabriela F P de Souza; Maria Jose Cuevas; Marcelo G de Oliveira; Norma Possa Marroni; Javier González-Gallego; María Jesús Tuñón
Journal:  J Mol Med (Berl)       Date:  2010-01-09       Impact factor: 4.599

Review 9.  Vascular pathobiology in chronic liver disease and cirrhosis - current status and future directions.

Authors:  Yasuko Iwakiri; Vijay Shah; Don C Rockey
Journal:  J Hepatol       Date:  2014-06-06       Impact factor: 25.083

10.  N-acetyl-L-cysteine increases MnSOD activity and enhances the recruitment of quiescent human fibroblasts to the proliferation cycle during wound healing.

Authors:  Gaowei Mao; Monali Goswami; Amanda L Kalen; Prabhat C Goswami; Ehab H Sarsour
Journal:  Mol Biol Rep       Date:  2015-12-15       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.